ACTA PHARMA REPORTS

Review Article | Journal homepage: https://pharma.researchfloor.org/ | ISSN: 3041-5381

Mechanisms of Antibiotic Resistance: Understanding the Molecular and Genetic Basis of Bacterial Resistance

Iheakolam Uchenna Caleb[1], Moses Adondua Abah*[2,3], Micheal Abimbola Oladosu[3,4], Micah Nnabuko Okwah[5,6], Nathan Rimamsanati Yohanna[2,3], Abah Sarah Onyeoche[7], Emmanuel Godwin Ogunjobi[8], Ebenezer Morayo Ale[2], Ismaila Emmanuel Oluwasegun[9], Ejim Thomas Ejim[10] and Amarachukwu Bernaldine Isiaka[11]

[1]*Department of Microbiology, Faculty of Biological and Physical Sciences, Abia State University, Uturu, Abia State, Nigeria*
[2]*Department of Biochemistry, Faculty of Biosciences, Federal University Wukari, Taraba State, Nigeria*
[3]*ResearchHub Nexus Institute, Nigeria*
[4]*Department of Biochemistry, Faculty of Basic Medical Sciences, University of Lagos, Lagos State, Nigeria*
[5]*Department of Internal Medicine, Cardiology Unit, Lagos University Teaching Hospital, Lagos State, Nigeria*
[6]*Department of Chronic Disease Epidemiology, Yale University, Connecticut, United States*
[7]*Department of Nursing, College of Health Sciences, Benue State University, Makurdi, Nigeria*
[8]*Department of Microbiology, Faculty of Science, Adekunle Ajasin University, Akungba-Akoko, Ondo state, Nigeria*
[9]*Project Center for Agro Technologies, Skolkovo Institute of Science and Technology, Moscow, Russian Federation*
[10]*Department of Surgery, Faculty of Clinical Sciences, University College Hospital, Ibadan, Oyo State, Nigeria*
[11]*School of Public Health, University of Port Harcourt, Rivers State, Nigeria*

ABSTRACT

The rise of antibiotic resistance is a pressing global health concern. Bacteria have evolved clever mechanisms to evade the effects of antibiotics, rendering many treatments ineffective. This resistance arises from a combination of genetic mutations, horizontal gene transfer, and environmental adaptations. At the heart of this issue are several key mechanisms. Some bacteria produce enzymes that degrade antibiotics, like β-lactamases that break down β-lactam antibiotics. Others modify their target sites, such as altering ribosomal proteins to evade antibiotic binding. Efflux pumps are another strategy, actively removing antibiotics from the cell. Reduced permeability and biofilm formation also contribute to resistance. This review explores the mechanisms of antibiotic resistance with emphasis on understanding the molecular and genetic basis of bacterial resistance.Research has revealed the intricate molecular basis of these mechanisms. Genetic mutations in target genes, such as gyrA, can confer resistance to fluoroquinolones. Horizontal gene transfer spreads resistance genes via plasmids, transposons, or integrons, accelerating the spread of resistance. Enzyme-mediated degradation is a potent strategy, with β-lactamases hydrolysing β-lactam antibiotics and aminoglycoside-modifying enzymes inactivating aminoglycosides.The findings highlight the complexity of antibiotic resistance. Efflux pumps, like AcrAB-TolC, are overexpressed in resistant strains, reducing intracellular antibiotic concentrations. Target modifications, such as altered penicillin-binding proteins, confer β-lactam resistance. Biofilms, with their protective extracellular matrices, shield bacteria from antibiotics and host defences.In the end, understanding these mechanisms is crucial for developing effective strategies to combat resistance. A One Health approach, combining antibiotic stewardship, surveillance, and novel therapeutic development, is essential to address this global threat. By unravelling the molecular basis of resistance, we can develop targeted therapies and stay ahead of the evolving bacterial threat.

***Keywords**: Antibiotic resistance, Genetic mutations, Efflux pumps, Biofilms, and Enzyme-mediated degradation.*

14 September 2025: Received
16 October 2025: Revised
10 November 2025: Accepted
04 December 2025: Available Online

Citation: Iheakolam Uchenna Caleb, Moses Adondua Abah, Micheal Abimbola Oladosu, Micah Nnabuko Okwah, Nathan Rimamsanati Yohanna, Abah Sarah Onyeoche, Emmanuel Godwin Ogunjobi, Ebenezer Morayo Ale, Ismaila Emmanuel Oluwasegun, Ejim Thomas Ejim and Amarachukwu Bernaldine Isiaka (2025). Mechanisms of Antibiotic Resistance: Understanding the Molecular and Genetic Basis of Bacterial Resistance. *Acta Pharma Reports.*
DOI: https://doi.org/10.51470/APR.2025.04.02.51

*Corresponding Author: **Moses Adondua Abah**
Email Address: **m.abah@fuwukari.edu.ng**

Introduction

One of the most ground-breaking medical discoveries of our time, antibiotics have reduced worldwide morbidity and mortality and completely altered the way infectious diseases are treated [1]. Since penicillin's discovery in the early 20th century, antibiotics have helped treat once-fatal bacterial infections, simplified complex surgical operations, and aided immunocompromised patients undergoing chemotherapy or organ transplants [2]. Their extensive use has not only extended life expectancy but also improved public health around the world, saving countless lives. Antibiotics have been a game-changer in medicine for decades, but their incredible efficacy has been undermined by the relentless development of antibiotic resistance. You may find a summary of the most common antibiotics, diseases that cause resistance, and the patterns of resistance in the organisms that cause this resistance in the table below [3].

The shocking worldwide impact of antimicrobial resistance (AMR) is immense.

Recent systematic estimates indicate that AMR was directly responsible for around 1.27 million fatalities in 2019 alone, and was associated with over 5 million deaths worldwide [4]. Clinical burden is worsened by the financial consequences of resistant infections, which lead to increased medical costs, decreased productivity, and lengthier hospital admissions. The potential for AMR to destabilize health systems and reduce the efficacy of vital medical therapies has led the World Health Organization (WHO) to rank it as one of the top ten global public health concerns [5]. The effect is more noticeable in low- and middle-income countries since novel drugs and diagnostic resources are scarce in these areas [6].

Table 1. Major antibiotic classes and resistant pathogens

Antibiotic Class	Common Resistant Pathogens	Mechanism of Resistance
β-lactams	*Escherichia coli*, *Klebsiella pneumoniae*	β-lactamase production, altered PBPs
Fluoroquinolones	*Pseudomonas aeruginosa*, *Neisseria gonorrhoeae*	Target site mutations, efflux pumps
Aminoglycosides	*Enterococcus faecalis*, *Acinetobacter baumannii*	Enzymatic modification, ribosomal mutations
Macrolides	*Streptococcus pneumoniae*, *Staphylococcus aureus*	Methylation of rRNA, efflux pumps
Glycopeptides	*Enterococcus faecium*	Altered cell wall precursors (VanA/VanB genes)

Source: *[16]*

Given the magnitude of the problem, understanding the genetic and molecular bases of resistance is crucial. Biofilm development, enzymatic drug degradation, target site alteration, and efflux pump activation are some of the bacteria's strategies for evading antibiotics [7, 8]. The genetic encoding of resistance determinants on integrons, transposons, and plasmids facilitates horizontal gene transfer between species and accelerates the dissemination of resistant traits [9]. Interactions between genetic mobility and molecular mechanisms illustrate the complexity of resistance evolution, highlighting the need for comprehensive intervention and monitoring measures.

Molecular microbiology and genomes have come a long way, yet there are still mysteries that need to be solved. It is common for surveillance systems to miss some resistance factors, especially in resource-constrained situations. Weak drug development pipelines have also contributed to the paucity of novel antibiotics utilized in clinical settings during the last several decades [10]. Predictive models for resistance emergence are lacking, and our understanding of bacterial adaptation responses is inadequate, which hinders the development of long-lasting treatment options. To address these gaps, a multidisciplinary approach is required, combining molecular discoveries with clinical epidemiology and public health policy.

There are two main aims and purposes of this research. First, it seeks to provide a comprehensive explanation of the molecular, genetic, and biochemical mechanisms underlying bacterial resistance; second, it focuses on the many strategies employed by pathogens to evade antimicrobial activity. Secondly, it aims to highlight the clinical significance of these mechanisms and explore possible therapeutic methods, including the development of novel medications, alternate treatments, and improved monitoring systems. The purpose of this review is to bridge the gap between molecular biology and clinical practice in order to give a comprehensive overview of antibiotic resistance and to direct measures to reduce its global impact.

Literature review

Classification of Antibiotic Resistance

The complex phenomenon of antibiotic resistance is influenced by clinical procedures, environmental factors, and microbial genetics. Developing focused interventions and directing therapeutic choices requires an understanding of theirclassification. In general, resistance mechanisms can be divided into three categories: intrinsic versus acquired, phenotypic versus genotypic, and cross-resistance versus multidrug resistance. Each of these categories has unique treatment and surveillance implications.

Intrinsic vs Acquired Resistance

The natural, innate insensitivity of some bacterial species to particular antibiotics is known as intrinsic resistance. This resistance is not caused by previous exposure to antibiotics; rather, it is encoded in the bacterial genome. For instance, *Pseudomonas aeruginosa's* low outer membrane permeability and efflux systems make it inherently resistant to many β-lactams [11]. Similarly, due to the lack of target penicillin-binding proteins, Enterococcus species show intrinsic resistance to cephalosporins [12].

On the other hand, acquired resistance results from horizontal gene transfer or genetic mutations, which are frequently brought on by exposure to antibiotics. Because it can spread quickly among bacterial populations, this type of resistance is more dynamic and clinically concerning. Carbapenemase genes in Klebsiella pneumoniae and plasmid-mediated β-lactamase production in Escherichia coli are examples of mechanisms 13]. Multidrug-resistant (MDR) infections are primarily caused by acquired resistance, which presents serious problems for public health [14].

Phenotypic vs Genotypic Resistance

When bacteria with no known genetic resistance markers survive exposure to antibiotics, this is known as phenotypic resistance. Transient physiological conditions like biofilm formation, changed metabolic activity, or stress-induced tolerance can cause this [15]. For example, biofilm-forming *Staphylococcus aureu*s may be less susceptible to vancomycin if itdoes not carry van genes.Conversely, genotypic resistance is characterised by the existence of particular resistance genes or mutations that can be identified using molecular diagnostics. Examples include the rpoB mutations that confer rifampicin resistance in Mycobacterium tuberculosis and the mecA gene in methicillin-resistant *Staphylococcus aureus* (MRSA) [16]. Due to compensatory mechanisms or variability in gene expression, genotypic methods may not always correlate with phenotypic outcomes, despite providing quick and accurate detection [17].

Cross-Resistance and Multidrug Resistance

A phenomenon called cross-resistance occurs when an organism develops a defense mechanism that can withstand many antibiotics, even those belonging to the same class. For example, efflux pumps such AcrAB-TolC in *E. coli* can expel chloramphenicol and fluoroquinolones [18]. Because of this occurrence, empirical treatment becomes more complicated and antibiotic stewardship becomes more important. Cumulative genetic events are a common source of multidrug resistance (MDR), which is defined as resistance to three or more classes of antimicrobials.

The persistence and association with nosocomial infections are hallmarks of multidrug-resistant (MDR) bacteria, such as *Acinetobacter baumannii, Klebsiella pneumoniae,* and *Pseudomonas aeruginosa* [19]. Multiple drug resistance (MDR) mechanisms, such as enzymatic degradation, target alteration, and membrane impermeability, are often encoded on mobile genomic elements that allow for rapid diffusion [20].

Table 2. Classification of antibiotic resistance with examples

Resistance Type	Description	Example Organism(s)	Mechanism/Genes Involved
Intrinsic	Natural insensitivity due to structural or functional traits	*Pseudomonas aeruginosa*, *Enterococcus spp.*	Low permeability, lack of target proteins
Acquired	Resistance gained via mutation or gene transfer	*E. coli*, *K. pneumoniae*	β-lactamases, carbapenemases
Phenotypic	Temporary resistance due to physiological state	*S. aureus* in biofilms	Biofilm formation, metabolic dormancy
Genotypic	Resistance due to identifiable genetic markers	MRSA, *M. tuberculosis*	mecA, rpoB mutations
Cross-resistance	One mechanism confers resistance to multiple drugs.	*E. coli*, *Salmonella spp.*	Efflux pumps (AcrAB-TolC)
Multidrug resistance	Resistance to ≥3 antibiotic classes	*A. baumannii*, *K. pneumoniae*	Enzymes, efflux pumps, gene clusters

Source: *[23]*

Molecular Mechanisms of Antibiotic Resistance

Bacteria use a wide range of molecular tactics to withstand antimicrobial pressure, which leads to antibiotic resistance. Treatment is made more difficult by the multidimensional resistance phenotypes that result from these mechanisms' frequent overlap rather than their isolation [21]. The molecular landscape is dominated by four main categories: active efflux pumps, altered drug targets, decreased drug permeability, and enzymatic drug inactivation. Each mechanism highlights the critical need for new therapeutic approaches and reflects the adaptability of bacteria.

β-lactamases: Enzymes known as β-lactamases hydrolyze the β-lactam ring of antibiotics, rendering penicillins, cephalosporins, and carbapenems inert. Particularly harmful are carbapenemases such as KPC, NDM, and OXA-type enzymes, as well as extended-spectrum β-lactamases (ESBLs) because to their broad substrate range and extensive distribution [22].

Enzymes that modify aminoglycosides (AMEs):A class of enzymes known as aminoglycoside (AME) enzymes Bacteria make acetyltransferases, nucleotidyltransferases, and phosphotransferases to protect ribosomal targets against aminoglycoside attachment. Pseudomonas aeruginosa and Enterobacteriaceae are very resistant because of these enzymes [23]. The inactivation of β-lactam antibiotics by β-lactamase enzymes is shown in Figure 1 through two main metabolic pathways**.**



Figure 1. A schematic showing β-lactam hydrolysis by β-lactamases and aminoglycoside modification by AMEs.)
Source: *[12]*

Panel A: Mechanism of serine β-lactamase

In this process, the antibiotic's β-lactam ring is attacked by a serine residue in the enzyme's active site, creating a covalent acyl-enzyme intermediate. Water quickly hydrolyses this intermediate, producing an inactive antibiotic molecule. Class A, C, and D β-lactamases, which are present in *Pseudomonas aeruginosa, Klebsiella pneumoniae*, and *Escherichia coli*, share this mechanism [24].

Panel B: Mechanism of metallo-β-lactamase

On the other hand, a zinc ion (Zn^{2+}) coordinated by histidine residues is used by metallo-β-lactamases (MBLs) to activate a water molecule that hydrolyses the β-lactam ring directly. Class B enzymes like NDM, VIM, and IMP, which are common in strains resistant to carbapenem, exhibit this non-covalent mechanism [25].

Alteration of Drug Target

Ribosomal mutations: Aminoglycoside and macrolide resistance is conferred by mutations in 16S rRNA or ribosomal proteins. For instance, macrolide binding is inhibited when erm genes methylate 23S rRNA [25]. Changes in penicillin-binding proteins (PBPs) decrease the binding of β-lactam antibiotics. PBP2a, which has a low affinity for β-lactams, is encoded by the mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) [26].

DNA gyrase and topoisomerase IV mutations: Point mutations in the gyrA and parC genes that change the quinolone-binding pocket cause fluoroquinolone resistance. There have been more reports of these mutations in Klebsiella pneumoniae and Escherichia coli [27].

Reduced Drug Permeability

The outer membrane of gram-negative bacteria serves as a selective barrier. Loss or remodelling of porins can lead to resistance, which lowers the influx of antibiotics. Porin loss: In E. coli, mutations or downregulation of porins like OmpF and OmpC restrict the entry of β-lactams and fluoroquinolones [28].Membrane remodelling: Permeability can be decreased by structural alterations in lipid composition. To withstand polymyxins, for instance, Pseudomonas aeruginosa alters its outer membrane [29].

Active Efflux Pumps

Antibiotics are actively removed from bacterial cells by efflux pumps, which reduce intracellular concentrations. They fall into the following major families namely; ATP-binding cassette (ABC) transporters which exportsmedications by hydrolysing ATP and Major Facilitator Superfamily (MFS) whose transport is dependent on the proton motive force [30].

Resistance-nodulation-division (RND) family: Common in Gram-negative bacteria, such as MexAB-OprM in *P. aeruginosa* and AcrAB-TolC in *E. coli*[31].

Broad-spectrum resistance is provided by efflux pumps, which frequently overlap with other mechanisms. Global stress responses and transcriptional regulators are involved in their intricate regulation [32]. Figure 2 depicts the structural organisation of the AcrAB-TolC multidrug efflux pump, a prototypical RND-family system in Gram-negative bacteria:



Figure 2. Efflux pump architecture
Source: *[31]*

The structural representation of the AcrAB-TolC multidrug efflux pump, a representative system of the RND family in Gram-negative bacteria, is displayed in Figure 2: The blue protein TolC is responsible for opening a pathway across the cell membrane. The AcrB (purple) substrate transporter is located within the inner membrane. By bridging the periplasmic gap, AcrA (green) attaches AcrB to TolC and stabilizes the complex [15].
This tripartite system actively expels a range of antibiotics, including chloramphenicol, β-lactams, and fluoroquinolones, from the cytoplasm to the outside world by means of the proton motive force. All of these factors contribute to the development of multidrug resistance and ensure efficient drug clearance [5, 10, 22].

Genetic Basis of Resistance
Antibiotic resistance is more than just a physiological phenomenon; it has profound implications for the genetic composition and evolutionary dynamics of bacterial populations. The introduction and spread of resistance characteristics among different microbial communities are driven by chromosomal mutations and horizontal gene transfer (HGT) [23]. In both environmental and clinical settings, resistance is more likely to persist due to biofilms' role as ecological niches that facilitate gene exchange and protect resistant phenotypes.

Mutations in the Chromosome
The structure or function of antibiotic targets can be changed by chromosomal mutations, which are induced or spontaneous changes in bacterial DNA. Reduced drug binding or changed cellular pathways can result from these mutations, which can happen in genes encoding ribosomal proteins, DNA gyrase, RNA polymerase, or metabolic enzymes [24].

Target site mutations: For instance, by altering the quinolone-binding site of DNA gyrase and topoisomerase IV, point mutations in the gyrA and parC genes provide resistance to fluoroquinolones [25]. Similarly, by changing the RNA polymerase β-subunit, mutations in the rpoB gene cause rifampicin resistance in Mycobacterium tuberculosis [26].

Regulatory mutations: By altering promoter regions or transcriptional regulators, resistance can be indirectly increased by upregulating efflux pumps or downregulating porins. For example, in Escherichia coli, mutations in the marR gene increase the expression of the AcrAB-TolC efflux system [27].

Fitness compensation: Bacteria frequently acquire compensatory mutations that restore growth rates without losing resistance, enabling long-term persistence, even though resistance mutations may impose fitness costs [28].
Table 3 displays Resistance genes encode proteins or mutations that counteract the effects of antibiotics through target modification (e.g., mecA, rpoB, gyrA), drug inactivation (e.g., β-lactamases, aminoglycoside-modifying enzymes), or alternative pathways (e.g., sul genes, tet genes). They are essential to the worldwide antimicrobial resistance crisis because their presence on plasmids, transposons, and integrons speeds up their spread throughout bacterial populations.

Table 3. Key resistance genes and associated antibiotics

Resistance Gene	Associated Antibiotic(s)	Mechanism of Resistance	Example Pathogen(s)
blaCTX-M, blaTEM, blaSHV	Penicillins, Cephalosporins	Extended-spectrum β-lactamase (ESBL) hydrolysis	*E. coli*, *K. pneumoniae*
blaNDM, blaKPC, blaOXA-48	Carbapenems	Carbapenemase-mediated hydrolysis	*K. pneumoniae*, *A. baumannii*
mecA	Methicillin, other β-lactams	Altered PBP2a with low β-lactam affinity	MRSA (*S. aureus*)
vanA, vanB	Vancomycin	Modified cell wall precursors (D-Ala-D-Lac)	*Enterococcus faecium*
rpoB	Rifampicin	Mutations in RNA polymerase β-subunit	*Mycobacterium tuberculosis*
gyrA, parC	Fluoroquinolones	Mutations in DNA gyrase/topoisomerase IV	*E. coli*, *Salmonella spp.*
erm genes (ermA, ermC)	Macrolides	rRNA methylation preventing drug binding	*Streptococcus pneumoniae*
aac(6′)-Ib, aph(3′)-IIIa	Aminoglycosides	Enzymatic modification (acetylation, phosphorylation)	*Enterobacteriaceae*, *P. aeruginosa*
sul1, sul2	Sulfonamides	Altered dihydropteroate synthase	*E. coli*, *Shigella spp.*
tet(M), tet(K)	Tetracyclines	Ribosomal protection proteins or efflux pumps	*Staphylococcus aureus*, *Enterococcus spp.*

Source: *[20]*

Horizontal Gene Transfer
The transfer of genetic material between organisms outside of conventional reproduction is known as horizontal gene transfer. It facilitates the quick spread of resistance genes among species and genera and is the main cause of acquired resistance Figure3.

Plasmids
Plasmids are autonomously replicating pieces of extrachromosomal DNA that often carry several resistance genes. Plasmids that code for conjugative transfer mechanisms allow for the direct transfer of genes from one cell to another. Plasmids are commonly seen in Enterobacteriaceae and carry extended-spectrum β-lactamases (ESBLs) such as bla_CTX-M, bla_TEM, and bla_SHV [29]. Furthermore, carbapenemases encoded by plasmids like bla_NDM, bla_KPC, and bla_OXA-48 have proliferated globally, primarily in Acinetobacter baumannii and Klebsiella pneumoniae [30].

Transposons
"Jumping genes," or transposons, are segments of DNA that may move freely inside and between genomes. The ability to integrate into chromosomes or plasmids is often facilitated by their presence of resistance genes and insertion sequences. β-lactamase genes are carried by Tn3 family transposons, which are frequently found in multidrug-resistant strains. The genes for tetracycline and aminoglycoside resistance are carried by Tn7 and Tn10, respectively, which incorporate into conserved chromosomal locations [32].

Integrons
Genetic platforms known as integrons capture and express gene cassettes, which may include resistance determinants. They consist of a recombination site (attI), an integrase gene (intI), and a cassette expression-controlling promoter. Class 1 integrons are the most important in clinical settings because they often contain multiple resistance cassettes, such as aadA, dfrA, and sul1, which confer resistance to trimethoprim, aminoglycosides, and sulfonamides [11].

Role of Biofilms in Gene Dissemination
Structured microbial communities embedded in an extracellular matrix that they produce themselves are known as *biofilms.* They develop on tissues, medical equipment, and environmental surfaces, giving bacteria a safe haven.

Physical defence: The biofilm matrix inhibits the penetration of antibiotics and produces oxygen and nutrient gradients, which trigger stress reactions that increase tolerance [16].

Enhanced HGT: Because biofilms promote stable microenvironments and close cell proximity, conjugation, transformation, and transduction occur more frequently. Compared to planktonic cultures, biofilms have much higher plasmid transfer rates [30].

Resistance persistence: Biofilm-resistant cells are able to withstand therapy and spread infections. For instance, multidrug-resistant subpopulations that avoid immune clearance are present in Pseudomonas aeruginosa biofilms in the lungs of people with cystic fibrosis [33].



Figure 3. Horizontal gene transfer mechanisms
Source: *[32]*

Clinical and Public Health Implications
Not only is antibiotic resistance a molecular or genetic phenomenon, but it also directly affects patient outcomes, healthcare costs, and global health security in clinical practice and public health systems. The ramifications are extensive, encompassing the emergence of resistant pathogens in hospitals and communities, treatment failure in individual patients, and the wider ecological aspects encompassed by the One Health viewpoint.

Unsuccessful Treatment
One of the most obvious clinical consequences of antibiotic resistance is treatment failure, which occurs when traditional medicines stop working against resistant infections. This failure increases the likelihood of complications, lengthens the disease, and ultimately increases the mortality rate. For example, colistin or linezolid, which are often used as last resorts but can be more harmful and less effective, are often necessary to treat infections caused by carbapenem-resistant Klebsiella pneumoniae or methicillin-resistant Staphylococcus aureus (MRSA) [21]. Furthermore, healthcare costs are increased and hospital stays are prolonged due to treatment failure. It is common for resistant illnesses to require multiple rounds of therapy, combination regimens, or experimental medicines, which can put a strain on healthcare resources. Resistance to rifampicin and isoniazid causes multidrug-resistant tuberculosis (MDR-TB), which in turn requires lengthy treatment courses with less effective and more expensive second-line drugs [12].

Resistance Acquired in a Hospital versus the Community
Hospital-acquired (nosocomial) and community-acquired antibiotic resistance present in different ways, each with unique clinical and epidemiological ramifications.

Hospital-Acquired Resistance
Because of their high antibiotic usage, invasive procedures, and susceptible patient populations, hospitals are hotspots for resistant pathogens. MRSA, multidrug-resistant *Acinetobacter baumannii*, and carbapenem-resistant Enterobacteriaceae are common hospital-acquired resistant organisms [13].

These infections are challenging to prevent and treat because they are frequently linked to catheters, ventilators, and surgical wounds. Because resistant infections greatly raise mortality rates in intensive care units, the burden is especially severe there.

Community-Acquired Resistance

Hospitals are no longer the only places where resistance occurs. Pathogens that spread widely outside of healthcare settings include resistant Neisseria gonorrhoeae and community-acquired MRSA (CA-MRSA). Resistant UTIs brought on by ESBL-producing E. coli are becoming more frequent in many areas among otherwise healthy people [14]. Widespread antibiotic abuse, such as self-medication, incomplete courses, and over-the-counter access without a prescription, is reflected in community-acquired resistance.

One Viewpoint on Health

In addressing antibiotic resistance, the One Health framework highlights the interdependence of environmental, animal, and human health. Due to the use of antibiotics in veterinary care, agriculture, and environmental contamination, resistance genes and pathogens spread throughout these domains.

Human health: Overprescription and clinical abuse of antibiotics hasten the development of resistance in pathogens like Mycobacterium tuberculosis and Streptococcus pneumoniae.

Animal health: Antibiotics are frequently used to prevent disease and promote growth in livestock. This procedure favours resistant bacteria that can spread to humans through food chains, such as Salmonella and ESBL-producing E. coli [21].

Environmental health: Hospital waste, pharmaceutical production, and agricultural runoff all introduce antibiotic residues and resistant bacteria into soil and water systems. These environments serve as reservoirs for resistance genes, which can be transferred to human pathogens via horizontal gene transfer [15].

Strategies to Combat Antibiotic Resistance

Beyond traditional drug development, innovative, multi-faceted strategies are required to combat the rising tide of antibiotic resistance. Overuse and misuse of antibiotics have sped up resistance, limiting doctors' treatment options, despite their discovery in the 20th century. Today, the primary tactics used to combat resistance include antibiotic stewardship, the development of novel antimicrobials, and the exploration of alternative treatments such as phage therapy and CRISPR-based interventions. This paradigm shift toward precision-driven and long-term infection control is represented by the integration of various strategies.

Table 4. Emerging anti-resistance strategies

Strategy	Mechanism/Approach	Example/Outcome
Antibiotic stewardship	Optimized prescribing, diagnostics, regulation	Reduced misuse, improved patient outcomes
Novel antimicrobials	New targets (lipid II/III), antimicrobial peptides, anti-virulence drugs	Teixobactin, AMPs, quorum-sensing inhibitors
Phage therapy	Bacteriophage-mediated bacterial lysis, engineered phages	Effective against MDR *P. aeruginosa*
CRISPR-based approaches	Gene editing to remove resistance determinants, diagnostics	Elimination of *blaNDM-1*, rapid detection

Source: *[9]*

Antibiotic Stewardship

In order to make sure that patients get the correct medication for the proper amount of time, antibiotic stewardship programs (ASPs) work to optimize antibiotic use. To decrease needless prescriptions, prevent abuse, and slow the establishment of resistance, stewardship is crucial. There is evidence that antibiotic safety programs (ASPs) improve patient outcomes without increasing death rates and substantially reduce hospitals' unnecessary antibiotic use [28]. Community stewardship initiatives include outreach to the general population, stronger oversight of OTC sales, and the use of fast diagnostic technologies to inform treatment decisions. The most immediate and cost-effective way to reduce misuse and preserve antibiotic efficacy for future generations is stewardship, as summarized in Table 4.

Novel Antimicrobials

Unfortunately, there is still a lack of novel antibiotics in the pipeline, even though the need is great. Antimicrobial research has been revitalized, nevertheless, by recent advances in synthetic biology, genomics, and natural product discovery. Teixobactin is one of several novel medicines that have shown promise in combating Gram-positive bacteria that have developed resistance to multiple drugs [17]. In a similar vein, AMPs generated from host defense proteins are being investigated for their potential to inhibit the development of resistance and exert broad-spectrum antimicrobial action [20]. Alternative treatments, such as anti-virulence medications, which neutralize infections rather than eliminating them, provide hope for lowering the selection pressure for resistance [3]. By targeting new organelles and bringing new ways to evade traditional resistance pathways, these new antimicrobials broaden the treatment toolbox, as seen in Table 4.

Phage Therapy

Antibiotics are losing favor, but bacterophages—viruses that infect and destroy bacteria—are making a comeback. By selectively attacking just certain bacterial strains, phage treatment protects beneficial microbiota in the gut. Clinical experiments have shown that phages can effectively combat bacteria with resistance, including Staphylococcus aureus and Pseudomonas aeruginosa [17]. Phage engineering also allows for the delivery of antibiotic payloads or an increase in the lytic activity of the virus. Phages, in contrast to antibiotics, evolve in tandem with bacteria, which means they may eventually be able to overcome resistance. Regulatory obstacles, host-phage interaction variability, and the requirement for tailored phage cocktails are some of the remaining issues. Table 4 shows that phage therapy is a potential complementary treatment option for conventional antibiotic-resistant illnesses.

CRISPR-Based Approaches

CRISPR-Cas systems, originally discovered as bacterial adaptive immune mechanisms, are now being harnessed to combat resistance at the genetic level. CRISPR-based antimicrobials can selectively target and cleave resistance genes, effectively

resensitizing bacteria to antibiotics [7]. For instance, CRISPR-Cas9 constructs delivered via plasmids or phagemids have been used to eliminate *blaNDM-1* and *mecA* genes, restoring susceptibility in resistant strains. Beyond gene editing, CRISPR can be applied for rapid diagnostics, enabling precise detection of resistance determinants in clinical samples [24]. As summarised in Table 4, CRISPR-based approaches represent a cutting-edge strategy, offering precision medicine solutions that directly reverse resistance rather than merely bypass it.

Conclusion

Antibiotic resistance is a major problem in modern medicine because it jeopardizes world health and ruins decades of progress in controlling infectious diseases. Enzymatic drug inactivation, target alteration, decreased permeability, and efflux pump activity are some of the molecular and genetic mechanisms that underlie resistance, demonstrating the incredible adaptability of bacteria under selection pressure. An interconnected and ever-changing resistome that goes beyond clinical bounds is formed by these processes, which are enhanced by chromosomal mutations, horizontal gene transfer, and the ecological resilience of biofilms. Treatment failures, extended hospitalizations, and higher death are clinical implications, and the public health impact extends beyond communities, ecosystems, and hospitals.

Antibiotic resistance will require a long-term, coordinated effort to overcome. Antibiotic stewardship, the practice of making prudent and efficient use of existing antibiotics in order to reduce the incidence of resistance, must remain paramount. Investment in new antimicrobials, including medicines that exploit host defense peptides or take advantage of new bacterial targets, is critical to refill the dwindling treatment pipeline. Bacteriophage therapy and CRISPR-based interventions are two examples of alternative techniques that are ushering in a new era of personalized antimicrobial treatment by providing precise tools that can directly target resistant organisms or eliminate resistance genes.

In the end, it will need the persistent collaboration of academics, doctors, lawmakers, and communities to control antibiotic resistance. Science alone will not be enough to overcome resistance; political determination, citizen engagement, and global unity are all essential. Together, stewardship, innovation, and ecological consciousness can alter the trajectory of resistance, ensuring that antibiotics remain effective for centuries to come. Together, we have a big problem, but also an incredible opportunity: to revolutionize the way infectious diseases are treated in the future via scientific innovation and collaboration.

Acknowledgement: We thank all the researchers who contributed to the success of this research work.

Conflict of Interest: The authors declared that there are no conflicts of interest.

Funding: No funding was received for this research work

References

1. Alhazza, A., Oyegbesan, A., Bousoik, E., & Montazeri Aliabadi, H. (2025). Multidrug resistance: Are we still afraid of the big bad wolf? *Pharmaceuticals, 18*(6), 895.
2. Allen, R. C., Popat, R., Diggle, S. P., & Brown, S. P. (2022). Targeting virulence: Can we make bacteria less harmful? *Nature Reviews Microbiology, 20*(5), 291–305.
3. Aslam, B., Khurshid, M., Arshad, M. I., Muzammil, S., Rasool, M., Yasmeen, N., & Baloch, Z. (2021). Antibiotic resistance: One health one world outlook. *Frontiers in Cellular and Infection Microbiology, 11*, 771. Bikard, D., &Barrangou, R. (2023). CRISPR-based antimicrobials: Harnessing gene editing to fight resistance. *Nature Reviews Genetics, 24*(3), 157–171.
4. Bousoik, E., *et al*. (2025). Multidrug resistance and antimicrobial resistance: Therapeutic options to overcome drug treatment obstacles. *Molecules, 27*(3), 616.
5. Darby, E. M., Trampari, E., Siasat, P., Solsona Gaya, M., Alav, I., Webber, M. A., & Blair, J. M. A. (2022). Molecular mechanisms of antibiotic resistance revisited. *Nature Reviews Microbiology*. Frontiers in Microbiology. (2024). Emerging challenges in antimicrobial resistance: Implications for clinical practice and public health. *Frontiers in Microbiology, 15*, 1403168.
6. Gergova, R., Boyanov, V., Muhtarova, A., & Alexandrova, A. (2024). A review of the impact of streptococcal infections and antimicrobial resistance on human health. *Antibiotics, 13*(4), 360.
7. Impey, R. E., Hawkins, D. A., Sutton, J. M., & Soares da Costa, T. P. (2020). Overcoming intrinsic and acquired resistance mechanisms associated with the cell wall of Gram-negative bacteria. *Antibiotics, 9*(9), 623.
8. James, E., Ogbonna, B. O., Onwuchuluba, E. E., Ogbonna, C. A., Nwaodu, M. A., Ibeneme, G. C., Folaranmi, O., Nduka, S. O., Folaranmi, N., & Umeh, I. B. (2025). Antimicrobial resistance in Nigeria's healthcare system: A comprehensive narrative review and policy implications. *Discover Public Health, 22*(460).
9. Kiga, K., Tan, X. E., Ito, H., &Sato'o, Y. (2021). CRISPR-Cas systems for combating antimicrobial resistance. *Frontiers in Microbiology, 12*, 751.
10. Kornelsen, V., & Kumar, A. (2021). Update on multidrug resistance efflux pumps in *Acinetobacter spp.Antimicrobial Agents and Chemotherapy, 65*(7), e00514-21.
11. Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2021). Phage therapy: A renewed approach to combat antibiotic-resistant infections. *Cell Host & Microbe, 29*(6), 867–882.
12. Kumar, A., *et al*. (2021). Polymyxin resistance and membrane remodeling in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy, 65*(5), e00321-21.
13. Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J. A., Klugman, K., & Davies, S. (2023). Access to effective antimicrobials: A worldwide challenge. *The Lancet, 401*(10389), 102–115.
14. Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., & Lewis, K. (2022). A new antibiotic kills pathogens without detectable resistance. *Nature, 608*(7921), 455–462.
15. Maleka, S., Perves, N., Uddin, N., Chowdhury, M. K., & Amin, N. (2024). The vicious impact of antimicrobial resistance on global public health security and the role of healthcare systems and policy in combating AMR. *World Journal of Public Health, 9*(3), 17.
16. Marino, A., Maniaci, A., Lentini, M., Ronsivalle, S., Nunnari, G., Cocuzza, S., Parisi, F. M., Cacopardo, B., Lavalle, S., & La Via, L. (2023). The global burden of multidrug-resistant bacteria. *Epidemiologia, 6*(2), 21. MDPI.
17. Mookherjee, N., Anderson, M. A., Haagsman, H. P., & Davidson, D. J. (2021). Antimicrobial host defence peptides: Functions and clinical potential. *Nature Reviews Drug Discovery, 20*(5), 311–332.
18. Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., *et al*. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet, 399*(10325), 629–655.
19. Nishino, K., Yamasaki, S., Nakashima, R., Zwama, M., & Hayashi-Nishino, M. (2021). Function and inhibitory mechanisms of multidrug efflux pumps. *Frontiers in Microbiology, 12*, 737288.

20. Nocera, A. (2024). Mechanisms of antibiotic resistance in pathogenic bacteria: A comprehensive review. *Journal of Microbial Pathogenesis, 8*(3), 1–12.
21. Novelli, M., & Bolla, J. M. (2024). RND efflux pump induction: A crucial network unveiling adaptive antibiotic resistance mechanisms. *Antibiotics, 13*(6), 501. https://doi.org/10.3390/antibiotics13060501
22. O'Neill, J. (2022). Tackling drug-resistant infections globally: Final report and recommendations. *Review on Antimicrobial Resistance*. Retrieved from https://amr-review.org
23. Pintér, K., Domán, M., Wehmann, E., Gantelet, H., & Magyar, T. (2023). Comparative analysis of phenotypic and genotypic antibiotic susceptibility of *Pasteurella multocida*. *Antibiotics, 14*(9), 906.
24. PMC. (2023). Gyrase and topoisomerase IV: Recycling old targets for new antimicrobials. *Frontiers in Genetics, 22*(2), 180–190
25. Pulcini, C., Binda, F., Lamkang, A. S., Trett, A., Charani, E., Goff, D. A., &Harbarth, S. (2021). Developing core elements of antibiotic stewardship programmes in low- and middle-income countries. *Clinical Microbiology and Infection, 27*(6), 817–826.
26. Quadram Institute. (2022). Molecular mechanisms of antibiotic resistance revisited. Retrieved from
27. Sood, A., Ray, P., &Angrup, A. (2021). Phenotypic and genotypic antimicrobial resistance in clinical anaerobic isolates from India. *JAC-Antimicrobial Resistance, 3*(2), dlab044.
28. Ventola, C. L. (2021). The antibiotic resistance crisis: Causes and threats. *Pharmacy and Therapeutics, 46*(1), 12–21.
29. World Health Organization (WHO). (2024). WHO updates list of drug-resistant bacteria most threatening to human health. Retrieved from https://www.who.int/news/item/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health
30. Wright, G. D. (2007). The antibiotic resistome: The nexus of chemical and genetic diversity. *Nature Reviews Microbiology, 5*(3), 175–186
31. Zárate, S. G., De la Cruz Claure, M. L., Benito-Arenas, R., Revuelta, J., Santana, A. G., & Bastida, A. (2021). Overcoming aminoglycoside enzymatic resistance: Design of novel antibiotics and inhibitors. *Molecules, 23*(2), 284.
32. Zhou, G., Wang, Q., Wang, Y., Wen, X., Peng, H., Peng, R., Shi, Q., Xie, X., & Li, L. (2023). Outer membrane porins contribute to antimicrobial resistance in Gram-negative bacteria. *Microorganisms, 11*(7), 1690.